BMO Capital analyst Evan Seigerman reiterated an Outperform rating and $1,300.00 price target on Eli Lilly (NYSE: LLY).

The analyst commented: "Early Data for AJ1-11095 Impress at EHA - Supportive of LLY's BD Strategy; Early Ph 1 data shared at EHA for Lilly's recently acquired AJ1-11095 (Type 2 JAK2i) look competitive vs currently approved treatments. AJX-101 tested AJ1-11095 in a broad population of MF patients who failed type-1 JAK2is with the interesting early responses that we saw in the abstract release (here) remaining durable in the later cut presented at EHA. 70% of patients achieved a best SVR35 response at any time as of the 5/28/26 cut. While still early, these data appear highly competitive, postioning AJ1-11095 as a potentially best in class JAK2i."

For an analyst ratings summary and ratings history on Eli Lilly click here. For more ratings news on Eli Lilly click here.

Shares of Eli Lilly closed at $1133.00 yesterday.